BioGaia AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0017769995
SEK
130.90
0.9 (0.69%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

High Management Efficiency with a high ROE of 15.46%

 
2

Company has very low debt and has enough cash to service the debt requirements

3

With ROE of 25.32%, it has a very attractive valuation with a 8.98 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 12,150 Million (Small Cap)

stock-summary
P/E

35.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

27.62%

stock-summary
Debt Equity

-0.60

stock-summary
Return on Equity

25.32%

stock-summary
Price to Book

9.24

Revenue and Profits:
Net Sales:
373 Million
(Quarterly Results - Mar 2026)
Net Profit:
79 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
33.44%
0%
33.44%
6 Months
26.72%
0%
26.72%
1 Year
28.08%
0%
28.08%
2 Years
4.89%
0%
4.89%
3 Years
28.59%
0%
28.59%
4 Years
-73.64%
0%
-73.64%
5 Years
-67.4%
0%
-67.4%

BioGaia AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
15.54%
EBIT Growth (5y)
13.08%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.70
Sales to Capital Employed (avg)
0.88
Tax Ratio
21.81%
Dividend Payout Ratio
49.86%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
77.27%
ROE (avg)
15.46%

Valuation key factors

Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
8.98
EV to EBIT
24.34
EV to EBITDA
23.08
EV to Capital Employed
21.45
EV to Sales
7.15
PEG Ratio
NA
Dividend Yield
28.43%
ROCE (Latest)
88.12%
ROE (Latest)
25.32%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -15.43% vs 34.91% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -19.64% vs 49.92% in Dec 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "372.60",
          "val2": "440.60",
          "chgp": "-15.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "101.50",
          "val2": "133.50",
          "chgp": "-23.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "0.20",
          "chgp": "900.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "79.40",
          "val2": "98.80",
          "chgp": "-19.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "256.00%",
          "val2": "289.10%",
          "chgp": "-3.31%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 8.12% vs 9.73% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -5.29% vs -3.83% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,538.20",
          "val2": "1,422.70",
          "chgp": "8.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "476.60",
          "val2": "434.80",
          "chgp": "9.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.10",
          "val2": "1.40",
          "chgp": "335.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.30",
          "val2": "-13.40",
          "chgp": "82.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "332.80",
          "val2": "351.40",
          "chgp": "-5.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "293.80%",
          "val2": "287.60%",
          "chgp": "0.62%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQstock-summary

Mar'26
Dec'25
Change(%)
Net Sales
372.60
440.60
-15.43%
Operating Profit (PBDIT) excl Other Income
101.50
133.50
-23.97%
Interest
2.00
0.20
900.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
79.40
98.80
-19.64%
Operating Profit Margin (Excl OI)
256.00%
289.10%
-3.31%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2026 is -15.43% vs 34.91% in Dec 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is -19.64% vs 49.92% in Dec 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
1,538.20
1,422.70
8.12%
Operating Profit (PBDIT) excl Other Income
476.60
434.80
9.61%
Interest
6.10
1.40
335.71%
Exceptional Items
-2.30
-13.40
82.84%
Consolidate Net Profit
332.80
351.40
-5.29%
Operating Profit Margin (Excl OI)
293.80%
287.60%
0.62%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 8.12% vs 9.73% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -5.29% vs -3.83% in Dec 2024

stock-summaryCompany CV
About BioGaia AB stock-summary
stock-summary
BioGaia AB
Pharmaceuticals & Biotechnology
Biogaia AB is a Sweden-based company engaged in the development and sell of probiotic products, primarily based on the Lactobacillus reuteri bacteria. The Company’s activities are divided into three segments: Finished consumer products, which distributes tablets, drops, Oral Rehydration Solutions (ORSs), and oral health products, among others; Component products, which is responsible for the sale of LifeTop Straw and Life Top Cap, as well as of cultures as an ingredient in licensee products, such as infant formula and dairy products; and Other products, including animal health goods. It collaborates with Nestle, Gerber, Delta Medical, InfectoPharmm, Ferring Middle East, AllergyCare, and Ewopharma, among others. Furthermore, the Company operates worldwide through a number of subsidiaries, such as Biogaia Biologics Inc, CapAble AB, TwoPac AB and Infant Bacterial Therapeutics AB.
Company Coordinates stock-summary
Company Details
Kungsbroplan 3 , STOCKHOLM None : 112 27
stock-summary
Tel: 46 8 5552930046 073 5001111
stock-summary
Registrar Details